Navigation Links
Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Date:3/6/2008

- - 42,856,898

-------------------------------------------------------------------------

Cash provided

by financing

activities 12,114,394 241,400 18,780,189 96,253,751

-------------------------------------------------------------------------

Net increase

(decrease) in

cash and cash

equivalents

during the

period 3,223,585 (19,846) (8,897,159) 6,715,096

Cash and cash

equivalents,

beginning of

the period 3,491,511 3,511,357 12,408,516 -

-------------------------------------------------------------------------

Cash and cash

equivalents,

end of the

period 6,715,096 3,491,511 3,511,357 6,715,096

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Cash interest

received 1,392,866 940,100 993,097

-------------------------------------------------------------------------

-------------------------------------------------------------------------

To view the Company's Financial Statements and Management's Discussion and Analysis, please see the Company's 2007 Annual Filings which will be available on http://www.sedar.com and http://www.oncolyticsbiotech.com.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further i
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
3. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
4. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
5. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
6. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
7. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
8. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
9. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
10. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
11. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: ... 1360 Almshouse Road, Warrington, Pa. , Details: The ... to finding a cure for hepatitis B and improving the ... annual Crystal Ball on Friday, April 11 at Warrington Country ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
(Date:1/14/2014)... The largest international professional organization of scientists ... derivatives thereof has endorsed an educational program that ... challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural Product ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... Up, Net Loss Down, Cash Position Strong, as Pipeline ... Continues to ... EXEL ) today reported financial results for the full,year and fourth quarter ... compared to $98.7 million in,2006. The increase in revenues for the full ...
... Revenue Increased 69.8% to $7.7 million ... - Second Quarter Net Income Increased 67.5% to $1.7 million, - First Six Months Revenues ... Increased 65% to $3.2 million for the Same Period, - Growth Driven ... ...
... Afford Life-Saving Biopharmaceuticals, WASHINGTON, Feb. 14 ... legislation that would create a pathway for,FDA approval ... new print,advertisement that features a footprint in the ... The ad highlights how meaningful biogenerics legislation ...
Cached Biology Technology:Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 2Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 4Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 5Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 6Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 7Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 8Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 9Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 2Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 3Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 4Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 5Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 6Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 7Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 8
(Date:4/17/2014)... Cell Press journal Current Biology on April ... sex lives. The Brazilian insects, which represent four distinct ... are the first example of an animal with sex-reversed ... in several different animals, Neotrogla is the ... reversed," says Kazunori Yoshizawa from Hokkaido University in Japan. ...
(Date:4/17/2014)... the immune system may fight cancers and viral infections. ... to treat illness. , The research, in mice, suggests ... police" specialized squads of defenders that patrol only ... city, the body. , Scientists at Washington University School ... liver, skin and uterus each has dedicated immune cells, ...
(Date:4/16/2014)... museum collections two new species of yellow-shouldered bats have been unearthed ... Field Museum of Natural History and described in the open access ... the genus Sturnira are part of a recent discovery ... third one still waiting to be officially announced. , Up until ...
Breaking Biology News(10 mins):In sex-reversed cave insects, females have the penises 2Some immune cells defend only 1 organ 2Two new species of yellow-shouldered bats endemic to the Neotropics 2
... may help us think, in addition to its well-known ... brain cells. We hypothesize that blood ... a principle investigator in the McGovern Institute for Brain ... Journal of Neurophysiology. Many lines of evidence suggest that ...
... the jungles of Central and South America, a group ... food by following hordes of army ants and ... curator of genetic resources at the LSU Museum of ... witnessed this peculiarity in 1989 when he accompanied then-LSU ...
... have seen the potential for cleaning up contaminated sites by ... their roots. Then the plants break certain kinds of pollutants ... roots, stems and leaves or release into the air. The ... that the process is slow and halts completely when growth ...
Cached Biology News:MIT: blood may help us think 2LSU professor studies army-ant-following birds 2Scientists ramp up ability of poplar plants to disarm toxic pollutants 2Scientists ramp up ability of poplar plants to disarm toxic pollutants 3Scientists ramp up ability of poplar plants to disarm toxic pollutants 4